Stock Alert: Immunovant (IMVT) Trades 5.26% Higher June 23

Equities Staff  |

Today, Immunovant Inc (NASDAQ:IMVT) gained $0.2 to finish the day Thursday at $4.00.

The company opened at $3.83 and shares fluctuated between $4.04 and $3.77 with 286,567 shares trading hands.

Immunovant is averaging 343,455 shares traded over the last 30 days. They have fell 55.40% YTD.

Immunovant expects its next earnings on 2022-08-09.

For technical charts, analysis, and more on Immunovant visit the company profile.

About Immunovant Inc

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

To get more information on Immunovant Inc and to follow the company's latest updates, you can visit the company's profile page here: Immunovant Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?

Market Movers

Sponsored Financial Content